Ataturk University

atauni.edu.tr

Total trials

421

Active

107

Phase 3

2

Total enrollment

45,288

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 16 of 16 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Intrathecal Morphine3
Bupivacaine14
Propofol2
15 ml Bupivacaine Hcl 0.25%1
20 mL bupivacaine 0.25%1
Trocar-Site Bupivacaine Infiltration1
Intraperitoneal Bupivacaine spray1
Ibuprofen 600 mg1
diclofenac sodium1
Biodentine1
single nucleotide polymorphism1
Bupivacaine Infiltration1
Dexmedetomidine1
Sevoflurane1
Toluidine Blue O1
Bupivacaine-Lidocaine Combination1

Next readouts

  • 2025-07-10
  • 2025-11-07
  • 2026-04-01
  • 2026-05-02
  • 2026-06-01
  • 2026-06-01
  • 2026-06-15
  • 2026-08
  • 2026-08-01
  • 2026-12-01

Top conditions

  • Analgesia14
  • Anxiety14
  • Pain13
  • Postoperative Pain9
  • Stress9
  • Pain, Acute9
  • Periodontitis8
  • Epilepsy7

Frequently asked questions about Ataturk University

How many clinical trials does Ataturk University have on ClinicalTrials.gov?
Ataturk University is listed as the lead sponsor on 421 clinical trials in ClinicalTrials.gov, 107 of which are currently active (recruiting, enrolling, or ongoing).
How many of Ataturk University's trials are in Phase 3?
2 of Ataturk University's trials are in Phase 3, spread across 16 active drug programs.
What therapeutic areas does Ataturk University focus on?
Ataturk University's most-studied conditions on ClinicalTrials.gov are Analgesia, Anxiety, Pain, Postoperative Pain, Stress.
When are Ataturk University's next clinical trial readouts?
Ataturk University has 10 upcoming primary-completion readouts tracked here; the soonest is “Effect of Genetic Polymorphisms on Response to Preoperative NSAIDs in Endodontic Postoperative Pain Management”, expected around 2025-07-10.